Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER
| Autor: | Stevan G. Severtson, Elise Amioka, Zachary R Margolin, Janetta L. Iwanicki, Richard C. Dart, Scott E D Kreider |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Poison control Pain & Substance use Disorders Rate ratio Original Research Articles Internal medicine Abuse Deterrent Formulations medicine Humans Pain Management Prescription Drug Abuse Medical prescription Prescription Drug Misuse business.industry Extended-Release Opioid Analgesics General Medicine Odds ratio Drug diversion Opioid-Related Disorders Analgesics Opioid Anesthesiology and Pain Medicine Prescription opioid Delayed-Action Preparations Morphine Substance Abuse Treatment Centers Neurology (clinical) AcademicSubjects/MED00010 business Oxycodone medicine.drug |
| Zdroj: | Pain Medicine: The Official Journal of the American Academy of Pain Medicine |
| ISSN: | 1526-4637 1526-2375 |
| DOI: | 10.1093/pm/pnaa272 |
| Popis: | ObjectiveTo evaluate abuse, misuse, and diversion of Xtampza ER, an extended-release (ER) abuse-deterrent formulation (ADF) of oxycodone.MethodsAbuse, misuse, and diversion of Xtampza ER were assessed using Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System data sources. Xtampza ER was compared with immediate-release (IR) oxycodone, other ADF ER products combined, and non-ADF ER products combined.ResultsXtampza ER prescriptions increased 50-fold during the study period. In contrast, cases from poison centers, substance abuse treatment centers, and diversion were infrequent and did not increase. Adjusted for prescriptions dispensed, poison center exposures were greater for IR oxycodone (rate ratio [RR] = 2.3, P = 0.008), other ADF ER opioids (RR = 5.2, P ConclusionXtampza ER abuse, misuse, and diversion and tampering are low relative to other prescription opioid analgesics. Abuse and diversion did not increase over the study period. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|